Suzhou Shengdiya Biotechnology

Suzhou Shengdiya Biopharmaceutical is a prominent biotechnology company based in Suzhou, China, and serves as the core biologics research, development, and manufacturing subsidiary of Jiangsu Hengrui Pharmaceuticals. The company specializes in the creation of innovative therapeutic antibodies, including monoclonal antibodies, bispecifics, and antibody-drug conjugates (ADCs), primarily targeting oncology and autoimmune diseases. Its most significant achievement is the development and commercialization of AiRuiKa (camrelizumab), a PD-1 inhibitor that has become a standard of care for multiple cancers in China. Suzhou Shengdiya operates large-scale, state-of-the-art GMP manufacturing facilities that support both domestic supply and international clinical trials. As a vital component of Hengrui's innovation strategy, the company is instrumental in advancing a robust pipeline of next-generation biologics toward global markets.